Q1 EPS Estimates for FibroBiologics Raised by HC Wainwright

FibroBiologics Inc. (NASDAQ:FBLG) – Research analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for FibroBiologics in a research report issued on Thursday, February 26th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.07) for the quarter, up from their previous forecast of ($0.10). HC Wainwright currently has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for FibroBiologics’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at ($0.38) EPS, FY2028 earnings at ($0.50) EPS and FY2029 earnings at ($0.65) EPS.

A number of other research analysts also recently issued reports on FBLG. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a research report on Thursday, January 22nd. D. Boral Capital cut their target price on shares of FibroBiologics from $15.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $5.50.

FibroBiologics Stock Performance

FBLG opened at $0.33 on Monday. The stock has a market capitalization of $22.21 million, a PE ratio of -0.78 and a beta of -0.69. The stock’s 50 day moving average price is $0.29 and its 200-day moving average price is $0.39. FibroBiologics has a 52-week low of $0.22 and a 52-week high of $1.53.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.06.

Hedge Funds Weigh In On FibroBiologics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Yorkville Advisors Global LP purchased a new position in shares of FibroBiologics in the 3rd quarter worth about $278,000. Landscape Capital Management L.L.C. bought a new stake in FibroBiologics during the 3rd quarter valued at about $191,000. Geode Capital Management LLC raised its holdings in FibroBiologics by 20.7% in the 4th quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock worth $78,000 after acquiring an additional 59,813 shares during the last quarter. Cascade Financial Partners LLC raised its stake in shares of FibroBiologics by 11.7% in the second quarter. Cascade Financial Partners LLC now owns 290,581 shares of the company’s stock worth $181,000 after purchasing an additional 30,500 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in FibroBiologics by 287.3% during the 4th quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock valued at $52,000 after acquiring an additional 171,800 shares during the period.

Insider Transactions at FibroBiologics

In related news, General Counsel Ruben A. Garcia acquired 140,000 shares of the stock in a transaction on Thursday, December 11th. The stock was acquired at an average price of $0.34 per share, for a total transaction of $47,600.00. Following the completion of the purchase, the general counsel owned 140,000 shares of the company’s stock, valued at $47,600. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 13.00% of the company’s stock.

Key FibroBiologics News

Here are the key news stories impacting FibroBiologics this week:

• Positive Sentiment: HC Wainwright sharply raised EPS forecasts across 2026–2029 and cut expected near‑term losses (Q1–Q4 2026 now modeled around ($0.07)–($0.08); FY2026 now ($0.29) vs prior ($0.45)), and left a “Buy” rating with a $4 target — a clear analyst vote of confidence that likely lifted sentiment. MarketBeat HC Wainwright Coverage
• Positive Sentiment: Company narrative: FibroBiologics is positioned to transition into a clinical‑stage company, which is a material operational milestone that can unlock investor interest, potential collaborations, and later-stage valuation re‑rating as clinical data milestones approach. FBLG: Ready to Transition to Clinical-Stage Company
• Neutral Sentiment: HC Wainwright also provided a longer‑horizon forecast (including FY2030 estimates) — useful for modelers but farther out and more uncertain; long‑term forecasts can support upside case but carry execution risk. HC Wainwright Forecasts FibroBiologics FY2030 Earnings
• Negative Sentiment: D. Boral Capital cut its price target to $7.00, signaling reduced near‑term upside compared with prior expectations; the cut injects caution and shows analysts remain divided on timing/scale of commercial or clinical progress. D. Boral Capital Cuts FibroBiologics Price Target

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.